Methylhomatropine

Methylhomatropine

SCHEMBL30516140

C[N+]1(C)[C@@H]2CC[C@H]1CC(OC(=O)C(O)c1ccccc1)C2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 5/20 1.00
CHRM1 P11229 4/20 1.00
PABPC1 P11940 2/20 0.76
CHRM3 P20309 4/20 0.69
BLM P54132 2/20 0.69
LMNA P02545 2/20 0.65
CYP2D6 P10635 2/20 0.65
CYP2C9 P11712 1/20 0.65
HSD17B10 Q99714 1/20 0.65
SMN1; SMN2 Q16637 3/20 0.64
CHRM4 P08173 3/20 0.64
CHRM5 P08912 3/20 0.64
TDP1 Q9NUW8 1/20 0.64
APOBEC3A P31941 1/20 0.60
APOBEC3G Q9HC16 1/20 0.60
CYP2C19 P33261 1/20 0.57
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
TSHR P16473 1/20 0.56
NR1I2 O75469 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylhomatropine SCHEMBL17179980 1.00 CHRM2 (1.00) CHRM2CHRM1PABPC1CHRM3BLM
Methylhomatropine SCHEMBL16784195 1.00 CHRM2 (1.00) CHRM2CHRM1PABPC1CHRM3BLM
Methylhomatropine SCHEMBL20659943 0.99 CHRM2 (0.97) CHRM2CHRM1PABPC1CHRM3BLM
Methylhomatropine SCHEMBL29555824 0.99 CHRM2 (0.97) CHRM2CHRM1PABPC1CHRM3BLM
Methylhomatropine SCHEMBL77827 0.99 CHRM2 (0.97) CHRM2CHRM1PABPC1CHRM3BLM
Methylhomatropine SCHEMBL613580 0.99 CHRM2 (0.97) CHRM2CHRM1PABPC1CHRM3BLM
Phenactropinium SCHEMBL29387827 0.83 CHRM2 (0.70) CHRM2CHRM1PABPC1CHRM3BLM
Phenactropinium SCHEMBL8916468 0.83 CHRM2 (0.70) CHRM2CHRM1PABPC1CHRM3BLM
Methylatropine SCHEMBL34463463 0.83 CHRM2 (1.00) CHRM2CHRM1PABPC1CHRM3BLM
Methylatropine SCHEMBL824874 0.83 CHRM2 (1.00) CHRM2CHRM1PABPC1CHRM3BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11752086-B2 Topical formulations and methods MYOCEPT INC. (US) 2023-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11752086-B2 Topical formulations and methods KRT18, ANXA3, VIP CHRM2 3496/4885CHRM1 3820/4885PABPC1 2874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.